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Edited by Veli-Pekka LehtoAbstract It is known that c-kit+ cells are increased in heart
after infarction. The exact origins of the cardiac c-kit+ cells re-
main to be determined. We asked whether adipose tissue could be
a potential source of c-kit+ cells. Our data show that the number
of c-kit+ cells increased in adipose tissue derived stem cells when
cultured with conditioned medium from neonatal cardiomyocytes
grown under serum deprivation and hypoxia condition. We also
found that VEGF receptor Flk-1 is involved in c-kit up regula-
tion via ERK-mediated pathway.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Beltrami et al. reported the existence of Lin c-kit+ cells
with the properties of cardiac stem cells [1]. These cells are
self-renewing, clonogenic, and multipotent, giving rise to
myocytes, smooth muscle, and endothelial cells. Recently,
the origin of the cardiac c-kit+ was traced back to bone
marrow [2]. However, it is known that bone marrow derived
c-kit+ cells are CD45 positive whereas cardiac c-kit+ cells are
CD45 negative. We reasoned that cardiac c-kit+ cells could
also be derived from other tissue/organs. It has been shown
that adipose tissue derived stem cells (ASCs) contain CD45
plastic adherent mesenchymal stem cells that have both meso-
dermal and ectodermal capacity [3–5]. ASCs engrafted into
injured myocardium and that this engraftment is associated
with expression of cardiomyocytic markers by donor-derived
cells [6]. We demonstrated VEGF receptor Flk-1 activation
is responsible for spontaneous diﬀerentiation of human ASCs
into a cardiomyocyte phenotype via paracrine mechanism [7].
In the present study, we asked whether adipose tissue could
also be a potential source of c-kit+ cells and whether c-kit+
expression can be regulated by soluble factors released by neo-
natal cardiomyocytes exposed to serum deprivation/hypoxicAbbreviation: ASCs, adipose tissue derived stem cells
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doi:10.1016/j.febslet.2007.08.063condition and whether VEGF receptor Flk-1 plays a role in
c-kit+ expression in ASCs.2. Materials and methods
2.1. Isolation and culture of hASCs
Subcutaneous adipose tissue was obtained from patients undergoing
elective operations following the University Institutional Guidelines.
Cells were isolated from the fat tissue as described previously [8] with
modiﬁcations. Fat tissue was minced and incubated for 90 min at
37 C on a shaker with Liberase Blendzyme 3 (Roche) at a concentra-
tion of 4 units per gram of fat tissue in PBS. The digested tissue was
sequentially ﬁltered through 100 lm and 40 lm ﬁlters (Fisher Scien-
tiﬁc) and centrifuged at (450 · g) for 10 min. The supernatant contain-
ing adipocytes and debris was discarded and the pelleted cells were
washed twice with Hanks Balanced Salt Solution (Cellgro) and ﬁnally
resuspended in growth media. Growth media contained a-modiﬁcation
of Eagle’s medium (aMEM, Cellgro), 20% FBS (Atlanta Biologicals),
2 mM glutamine (Cellgro), 100 U/ml penicillin with 100 lg/ml strepto-
mycin (Cellgro). Plastic adherent cells were designated human adipose
tissue-derived stem cells (hASCs) and grown in a-MEM containing
20% fetal bovine serum. Flk-1 and Flt-1 neutralizing antibodies were
purchased from R&D Systems. Kinase inhibitors (PD098059 and
JNK II) were purchased from Calbiochem.
2.2. Flow cytometric analysis of phenotype in hASCs
hASCs of the third passage from 3 donors were used for phenotype
analysis. Cell aliquots (1 · 106 cells/1 ml) were stained with primary
antibodies at room temperature for 30 min. The primary antibodies
were ﬂuorescein isothiocyanate (FITC)-conjugated anti-human CD44
(Chemicon), CD34, CD90, HLA-DR (USBiological) or phycoerythrin
(PE)-conjugated anti-human CD11b, CD105 (eBioscience), CD14,
CD45 (USBiological). Monoclonal antibody against c-kit was pur-
chased from Sigma. Isotype-matched normal mouse IgGs (Chemicon)
were used as controls. Flow cytometry was performed on a ﬂuores-
cence-activated cell sorter (FACSCalibur, BD Biosciences, San Jose,
CA) and data analysis was performed with Cell Quest software (Bec-
ton-Dickinson).
2.3. Adipogenic diﬀerentiation
The adipogenic diﬀerentiation potential for stem cells was analyzed
as described previously [9,10]. The cells of passage three were harvested
using trypsin/EDTA and plated in 24-well plates at 30,000 cells/cm2 for
16 h to allow attachment. At 100% conﬂuency, cells were then switched
to adipogenic medium containing low glucose Dulbeco’s modiﬁcation
of Eagle’s medium (DMEM) supplemented with 10% FBS, 2 mM
L-glutamine, 100 U/ml penicillin, 100 lg/ml streptomycin (Cellgro)
100 lM L-ascorbate acid (Sigma), 1 lM dexamethasone, 0.5 mM
1-methyl-3-isobutylxanthine (IBMX), 100 lM indomethacin and
10 lg/ml human recombinant insulin (Sigma) for 21 days. Cells of
the control group were cultured in low glucose DMEM plus 10%
FBS (control medium). Medium were changed every three days.
Adipogenesis of ASCs was assessed by staining cells with Oil Red O
(Sigma).blished by Elsevier B.V. All rights reserved.
Fig. 1. Characterization of human ASCs. Human ASCs are spindle
shaped and plastic adherent when cultured in a-MEM containing 20%
FBS.
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Osteogenic diﬀerentiation [11] was assessed by incubating the cells of
100% conﬂuence with high-glucose DMEM plus 10% FBS supple-
mented with 0.1 lM dexamethasone, 200 lM L-ascorbic acid, and
10 mM b-glycerol phosphate (Sigma). Media was changed every three
days for three weeks. Cells of the control group were cultured in high-
glucose DMEM plus 10% FBS for three weeks. To assess mineraliza-
tion, calcium deposits in cultures were stained with Alizarin red stain
(Sigma).
2.5. Neurogenic diﬀerentiation
Trypsinized cells at passage 3 were added on the coverslips coated
with ﬁbronectin in wells at a density of 3 · 104 cells per cm2 in aMEM
containing 20% FBS and antibiotics. The medium was replaced the fol-
lowing day by induction medium containing DMEM/F12, 1% FBS,
2% B27 (Invitrogen), 10 ng/ml bFGF (Chemicon), 10 ng/ml EGF,
10 lM forskolin, 1 mM cAMP (for human 2 Mm), 5 lg/ml insulin,
0.5 mM 1-methyl-3-isobutylxanthine, 1 mM 2-mercaptoethanol,
50 lM Vitamin C (Sigma), 10 ng/ml NGF (R&D) for 21 days. Cells
were ﬁxed with methanol at 20 C for 10 min and washed, and immu-
nocytochemistry performed using standard methods. In brief, cells
were blocked with 10% donkey serum and then incubated with a poly-
clonal antibody against a MAb against microtube related protein-2
(MAP-2, abcam) overnight at 4 C. After washing, cells were incubated
with Alex-488 donkey anti-rabbit antibody (1:1000, Invitrogen). A
Zeiss microscope (Germany) with a camera and controller software
was used to capture images.
2.6. Hepatogenic diﬀerentiation
Trypsinized cells at passage 3 were added on the coverslips coated
with ﬁbronectin at a density of 3 · 104 cells per cm2 in aMEM contain-
ing 20% FBS and antibiotics. The medium was replaced the following
day by induction medium containing DMEM (1 g/l glucose), 1% FBS,
10 ng/ml bFGF, 20 ng/ml aFGF (Chemicon), 1% ITS, 10 ng/ml EGF
(Sigma), 10 ng/ml OSM, 20 ng/ml HGF (R&D) for 21 days. Hepato-
genesis was veriﬁed by immunoﬂuorescence staining of hepatocytes
speciﬁc antigen albumin (abcam).
2.7. Cardiomyocyte extraction
Cardiomyocytes were obtained from neonatal Sprague-Dawley rats
following the guidelines of Veterinary Medicine and Surgery at MD
Anderson Cancer Center. For primary culture of Neonatal Rat
Cardiomyocytes (NRCMs) a commercial kit was used (Worthington).
Brieﬂy, the hearts were rinsed in HBSS, minced to pieces less than
1 mm3 in size. Trypsin (50 lg/ml) was added and the minced tissue
was incubated overnight at 2–4 C. Twenty-four hours later trypsin
inhibitor was added and the tissue was subsequently digested with col-
lagenase (300 U/ml) by incubating at 37 C for 45 min. The superna-
tant was ﬁltered through 70 lm cell strainer, centrifuged at 80 · g for
5 min and resuspended in Leibovitz L-15 Media and plated at a densityFig. 2. Flow cytometric analysis of surface markers. Flow cytometric analysi
are typical for mesenchymal stem cells. Black histograms indicate isotype-mof 100,000 cardiomyocytes per cm2. Beating myocytes were observed
within 18 h and used immediately for subsequent experiments. Condi-
tioned medium was concentrated with Centriprep Centrifugal Filter
Unit (Millipore).
2.8. Statistics
All values are presented as means ± standard deviation of the mean
(S.D.). Statistical analysis was performed using Student’s t-tests. A
level of p < 0.05 was considered as statistically signiﬁcant.3. Result
3.1. ASC characterization
These cells are plastic adherent, spindle shaped cells (Fig. 1).
The ASCs are positive for CD44 (99.36 ± 0.75%), CD90
(97.59 ± 2.45%), CD105 (98.51 ± 1.83%) and negative for
CD11b (0.33 ± 0.18%), CD14 (0.51 ± 0.11%), CD34 (1.09 ±
0.16%), CD45 (0.39 ± 0.29%) and HLA-DR (0.68 ± 0.92%)
(Fig. 2).s of surface markers demonstrated that ASCs express CD markers that
atched controls; red histograms show surface antigen expression level.
Fig. 3. Diﬀerentiation potential of hASCs. Cells were cultured in adipogenic (b), osteogenic (d), hepatogenic (f) and neurogenic induction medium
(h) or their respective control medium (a,c, e,g). Adipogenesis and osteogenesis of hASCs were conﬁrmed by Oil Red O staining (a,b) or Alizarin Red
S staining, respectively. Hepatogenesis and neurogenesis were veriﬁed by immunoﬂuorescence staining of hepatocytes speciﬁc antigen albumin or



























Fig. 4. c-Kit expression in ASCs. The bar graph summarizes the
results of experiments of ASCs exposed to conditioned medium of
cardiomyocytes. Control, ASC grown in aMEM containing 20% FBS
without conditioned medium; CM, conditioned medium from cardio-
myocytes; CMSH, conditioned medium from neonatal cardiomyocytes
grown under serum deprivation and hypoxia condition; Flk, neutral-
izing antibody against Flk-1 (0.3 lg/ml); Flt, Flt-1 neutralizing
antibody (8 lg/ml); PD, PD098059 (10 lM); JNK, JNK II inhibitor
(10 lM). Flk-1, Flt-1, PD, JNK were preincubated with ASCs for
30 min before conditioned medium from neonatal cardiomyocytes
grown under serum deprivation and hypoxia condition was added to
culture. *P < 0.05 versus control; n.s. not signiﬁcant versus control.
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To evaluate the multipotent capacity of hASCs, cells were
cultured in adipogenic and osteogenic induction medium for
three weeks. hASCs of the third passage from three donors
were used for the diﬀerentiation studies.
hASCs in adipogenic induction medium displayed character-
istic multiple intracellular oil droplets. These oil droplets
showed red vesicles when stained with Oil Red O stain
(Fig. 3b). No lipid droplets were observed in cells cultured in
control medium (Fig. 3a). Cells cultured in osteogenic induc-
tion medium showed calciﬁcation deposits from diﬀerentiated
osteoblasts (Fig. 3d) which was not observed in cells cultured
in control medium (Fig. 3c).
Cells cultured in the hepatogenenic induction medium
became small and polygonal epitheloid cell-like. Immunoﬂuo-
rescence staining showed that albumin, a speciﬁc marker for
hepatocytes [12], could be detected in cells cultured hepato-
genenic induction medium (Fig. 3f) but not in control medium.
(Fig. 3e). Cells exposed to the neurogenic medium exhibited
radical process like neuritis which are positive for MAP-II, a
speciﬁc marker of neuron (Fig. 3h). However cells cultured
in control medium did not express MAP-II (Fig. 3g).
3.3. c-Kit expression in ASCs
Neonatal cardiomyocytes were subjected to serum depriva-
tion and hypoxia for 48 h and the conditioned medium were
collected and concentrated 10 times. Adherent passage 3
human ASCs were cultured with the conditioned medium
(diluted 10· with fresh medium containing 20% FBS) for
72 h. Controls were incubated with conditioned medium from
cardiomyocytes grown under normal condition. We used ﬂow
cytometry to determine the percentage of c-kit+ cells in ASCs.
Our data showed that ASCs cultured with conditioned med-
ium from normal neonatal cardiomyocytes expressed only
1.46 ± 0.49% of c-kit+ cells whereas ASCs cultured with condi-
tioned medium from neonatal cardiomyocytes grown under
serum deprivation and hypoxia condition expressed
4.55 ± 0.61% of c-kit+ cells (P < 0.05) (Fig. 4). The increased
c-kit expression was blocked by VEGF receptor Flk-1 anti-
body (1.81 ± 0.84%) and by MAP kinase inhibitor PD98059
(2.39 ± 0.17%) but not by Flt-1 antibody (4.85 ± 1.1) or JNK
inhibitor II (4.47 ± 0.47%) (Fig. 4).4. Discussion
The major ﬁnding of the present study is that the percentage
of c-kit+ cells in adipose derived stem cells can be up regulated
when cultured with conditioned medium from neonatal cardio-
myocytes that has been subjected to hypoxia and serum depri-
vation. Our data also indicate that VEGF receptor Flk-1 is
involved in c-kit up regulation via ERK-mediated pathway.
Our ﬁndings suggest that adipose tissue may be a potential
source of c-kit+ cells which can be up regulated and mobilized
in response to ischemic injury in the heart.
The c-kit+ cells have been found in bone marrow and
heart [1]. Recent study by Fazel et al. demonstrated that
the putative cardiac c-kit+ stem cells are from bone marrow
[2]. This was demonstrated in an elegantly engineered GFP
bone marrow chimeric mice model. Seven days after myocar-
dial infarction, c-kit+ cells could be identiﬁed in the hearts
4684 X. Bai et al. / FEBS Letters 581 (2007) 4681–4684and 74% of the c-kit+ cells in the heart expressed GFP.
Therefore the conclusion was that cardiac c-kit+ cells were
recruited from bone marrow after myocardial infarction.
However, it does not rule out the possibility that c-kit+
cells could be derived from other sources since the remain-
ing 24% of the c-kit+ cells found in the heart were GFP neg-
ative.
Interestingly, bone marrow derived c-kit+ cells are CD45
positive whereas the cardiac c-kit+ cells are CD45 negative.
It was suggested that this phenomenon was due to CD45
down regulation [1,2]. It is also possible that stem cells
within adipose tissue may be recruited from bone marrow.
Crossno et al. [13] showed that rosiglitazone promotes
development of a novel adipocyte population from bone
marrow-derived circulating progenitor cells. This was demon-
strated nicely by transplanting whole BM cells from GFP-
expressing transgenic mice into wild-type C57BL/6 mice
and subjecting them to a high-fat diet or treatment with
the thiazolidinedione (TZD) rosiglitazone (ROSI) for several
weeks. They showed that after 3 weeks of ROSI treatment,
there was a 7.74-fold increase in GFP+ cells expressing a pat-
tern of cell-surface markers characteristic of mesenchymal
progenitor cells (CD45 Sca-1+) and these cells were also
found in collagenase-digested omental and intrascapular fat
pads. These data suggest that the stem cells within adipose
tissue may themselves be recruited from the marrow as circu-
lating CD45 Scal+ populations.
It is known that c-kit+ cells can diﬀerentiate into endothe-
lial cells. Along this line, Miranville et al. [14] demonstrated
the presence of endothelial progenitor cells in the stroma-
vascular fraction of adipose tissue. Planat-Benard et al. [15]
showed that adipose tissue contain progenitor cells that par-
ticipate in vascular-like structure formation in Matrigel plug
and enhance the neovascularization reaction in ischemic tis-
sue. The angiogenic potential of ASCs are likely mediated
by VEGF and related factors [16,17]. Importantly, ASCs
are regulated by hypoxia as shown by an elegant study per-
formed by Rehman et al. [17]. They demonstrated that ASCs
secreted signiﬁcant amount of VEGF, hepatocyte growth
factor (HGF), and transforming growth factor-b (TGF).
When ASCs were cultured in hypoxic conditions, VEGF
secretion increased 5-fold. Furthermore, conditioned media
obtained from hypoxic ASCs signiﬁcantly increased endothe-
lial cell growth and reduced endothelial cell apoptosis. Nude
mice with ischemic hindlimbs demonstrated marked perfu-
sion improvement when treated with human ASCs. Together,
these ﬁndings suggest that autologous delivery of ASCs may
be a novel therapeutic option to enhance angiogenesis or
achieve cardiovascular protection.
In conclusion, our results indicate that cells derived from
adipose tissue contain c-kit+ cells that can be up regulated
by soluble factors produced by cardiomyocytes exposed to
serum deprivation/hypoxia condition. Our data support the
potential for ASCs based therapies in the treatment of ischemic
heart diseases.
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